Last checked at 11 Jul 2017 14:59
Shield Therapeutics plc
("Shield" or the "Company")
Grant of Share Options
London, UK, 11 July 2017. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that the Company has today granted, in aggregate, 1,972,487 share awards in the form of options over Ordinary shares in the capital of the Company ("Ordinary Shares") under the Company's 2016 Long-term Incentive Plan ("LTIP") and the 2016 Company Share Option Plan ("CSOP"). The Company has granted 1,683,877 options under the LTIP and 288,610 options under the CSOP.
The LTIP options will be exercisable at a price of 1.5 pence per Ordinary Share, after a period of 3 years until the day before the tenth anniversary of the grant, subject to the achievement of clear performance criteria set out in the Company's Admission Document, a copy of which is available on the Company's website (www.shieldtherapeutics.com).
The CSOP options are exercisable at an exercise price of 157.5 pence per Ordinary Share from the third anniversary of grant until the day before the tenth anniversary of grant. There are no additional performance conditions attaching to the CSOP options.
This grant of options is part of the Company's long-term incentive arrangements designed to align the interests of the shareholders and executives.
In accordance with the requirements of the EU Market Abuse Regulation the following options have been granted to PDMRs under the LTIP and CSOP.
Name | LTIP options granted | Total number of LTIP options held following grant | CSOP options granted | Total number of CSOP options held following grant |
Carl Sterritt, CEO | 263,512 | 572,736 | 19,048 | 19,048 |
Joanne Estell, CFO | 285,714 | 285,714 | 19,048 | 19,048 |
Paul Steckler, PDMR | 162,698 | 356,618 | 19,048 | 19,048 |
Mark Sampson, PDMR | 165,952 | 321,088 | 19,048 | 19,048 |
Following the grant of the LTIP and CSOP options, the total number of Ordinary Shares outstanding under share incentive schemes arrangements will be 3,014,749 representing 2.59% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
LTIP
1 | Details of the person discharging managerial responsibilities/person closely associated
| |
a) | Name
| Carl Sterritt Director / PDMR Joanne Estell Director / PDMR Paul Steckler PDMR Mark Sampson PDMR
|
2 | Reason for the notification
| |
a) | Position/status
| All PDMRs of Shield Therapeutics |
b) | Initial notification/ Amendment
| Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
a) | Name
| Shield Therapeutics plc |
b) | LEI
| 213800G74QWY15FC3W71 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
a) | Description of the financial instrument, type of instrument
Identification code
| Option over ordinary shares of 1.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 |
b) | Nature of the transaction
| Grant of Options over ordinary shares in accordance with the Company's Long Term Incentive Plan |
c) | Price(s) and volume(s)
| Exercise price: 1.5p
Volumes: Carl Sterritt 263,512 Joanne Estell 285,714 Paul Steckler 162,698 Mark Sampson 165,952
|
d) | Aggregated information
-Aggregated volume
-Price
|
877,876
Exercise price: 1.5p |
e) | Date of the transaction
| 11 July 2017 |
f) | Place of the transaction
| Outside a trading venue |
CSOP
1 | Details of the person discharging managerial responsibilities/person closely associated
| |
a) | Name
| Carl Sterritt Director / PDMR Joanne Estell Director / PDMR Paul Steckler PDMR Mark Sampson PDMR
|
2 | Reason for the notification
| |
a) | Position/status
| All PDMRs of Shield Therapeutics |
b) | Initial notification/ Amendment
| Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
a) | Name
| Shield Therapeutics plc |
b) | LEI
| 213800G74QWY15FC3W71 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
a) | Description of the financial instrument, type of instrument
Identification code
| Option over ordinary shares of 157.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 |
b) | Nature of the transaction
| Grant of Options over ordinary shares in accordance with the Company's Share Option Scheme |
c) | Price(s) and volume(s)
| Exercise price: 157.5p
Volumes: Carl Sterritt 19,048 Joanne Estell 19,048 Paul Steckler 19,048 Mark Sampson 19,048
|
d) | Aggregated information
-Aggregated volume
-Price
|
76,192
Exercise price: 157.5p |
e) | Date of the transaction
| 11 July 2017 |
f) | Place of the transaction
| Outside a trading venue |
-Ends-
For further information please contact:
Shield Therapeutics plc | +44 (0)207 186 8500 |
Carl Sterritt, Chief Executive Officer Joanne Estell, Chief Financial Officer | |
Nominated Advisor and Joint Broker Liberum Capital Limited Christopher Britton/Steve Pearce
| +44 (0)20 3100 2222 |
Joint Broker Peel Hunt LLP James Steel/Dr Christopher Golden
|
+44 (0)20 7418 8900 |
Financial PR Advisor Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal
|
+44 (0)20 3709 5700 shieldtherapeutics@consilium-comms.com |
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.